Invion Limited (FRA:7C8)

Germany flag Germany · Delayed Price · Currency is EUR
0.0400
+0.0010 (2.56%)
Last updated: Dec 5, 2025, 8:03 AM CET
-83.87%
Market Cap 4.49M
Revenue (ttm) n/a
Net Income (ttm) -4.92M
Shares Out n/a
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 2
Open 0.0400
Previous Close 0.0390
Day's Range 0.0400 - 0.0400
52-Week Range 0.0295 - 0.2480
Beta n/a
RSI 61.08
Earnings Date Nov 27, 2025

About Invion

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 4
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 7C8
Full Company Profile

Financial Performance

Financial numbers in AUD Financial Statements

News

There is no news available yet.